The randomized multicentre MATRIX ( Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX ) trial has been designed to compare the clinical outcome of patients with acute coronary syndromes treated invasively according to the access site ( transfemoral vs. transradial ) and to the anticoagulant therapy ( bivalirudin vs. heparin ) .